James Cassidy
Cancer Research UK
Glasgow
UK
Name/email consistency: high
- Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Cassidy, J., Saltz, L.B., Giantonio, B.J., Kabbinavar, F.F., Hurwitz, H.I., Rohr, U.P. J. Cancer Res. Clin. Oncol. (2010)
- Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.S., Rivera, F., Couture, F., Sirzén, F., Saltz, L. J. Clin. Oncol. (2008)
- Cetuximab for the treatment of patients with colorectal cancer. Cassidy, J. Nature Clinical Practice. Oncology (2008)
- Which first-line treatment is superior in advanced colorectal cancer: XELOX or pviFOX?. Cassidy, J. Nature Clinical Practice. Oncology (2007)
- Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Cassidy, J., Douillard, J.Y., Twelves, C., McKendrick, J.J., Scheithauer, W., Bustová, I., Johnston, P.G., Lesniewski-Kmak, K., Jelic, S., Fountzilas, G., Coxon, F., Díaz-Rubio, E., Maughan, T.S., Malzyner, A., Bertetto, O., Beham, A., Figer, A., Dufour, P., Patel, K.K., Cowell, W., Garrison, L.P. Br. J. Cancer (2006)
- Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer. Cassidy, J. Clin. Colorectal. Cancer (2005)
- XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., Schöffski, P., Sobrero, A., Van Cutsem, E., Díaz-Rubio, E. J. Clin. Oncol. (2004)
- Tumour-targeted drug and gene delivery: principles and concepts. Cassidy, J., Schätzlein, A.G. Expert. Rev. Mol. Med (2004)
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., McKendric, J., Maroun, J., Marshall, J., Osterwalder, B., Pérez-Manga, G., Rosso, R., Rougier, P., Schilsky, R.L. Ann. Oncol. (2002)